• Publications
  • Influence
Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.
TLDR
It is the view of the AES Task Force on the Phenotype of PCOS that there should be acceptance of the original 1990 National Institutes of Health criteria with some modifications, taking into consideration the concerns expressed in the proceedings of the 2003 Rotterdam conference.
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.
TLDR
It is the view of the AE-PCOS Society Task Force that PCOS should be defined by the presence of hyperandrogenism, ovarian dysfunction, and/or polycystic ovaries, and the exclusion of related disorders.
Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.
TLDR
Relevant topics addressed-all dealt with in a systematic fashion-include adolescence, hirsutism and acne, contraception, menstrual cycle abnormalities, quality of life, ethnicity, pregnancy complications, long-term metabolic and cardiovascular health, and finally cancer risk.
The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.
TLDR
The Rotterdam and AES prevalence estimates were up to twice that obtained with the NIH criteria in this, as well as other prevalence studies, drawing attention to the issue of many women with PCOS in the community remaining undiagnosed.
Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome
TLDR
An expert panel in PCOS and CVD reviewed literature and presented recommendations, finding women with PCOS with obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance, and subclinical vascular disease are at risk, whereas those with metabolic syndrome and/or type 2 diabetes mellitus are at high risk for CVD.
Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.
TLDR
Women with PCOS had an elevated prevalence of IGT, DM2 and metabolic syndrome in both BMI and non-BMI-matched studies and further research is required.
Beta-Oxidation Is Essential for Mouse Oocyte Developmental Competence and Early Embryo Development1
TLDR
The importance of lipid metabolism for oocyte developmental competence and early embryo development was demonstrated by assessing the rate of embryo development following inhibition or upregulation of beta-oxidation with etomoxir (an inhibitor of CPT1B) or l-carnitine, respectively.
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
TLDR
Metformin is an effective treatment for anovulation in women with polycystic ovary syndrome and its choice as a first line agent seems justified, and there is some evidence of benefit on variables of the metabolic syndrome.
Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome.
TLDR
Overweight women with polycystic ovary syndrome were randomized to a high protein or a low protein diet, and improvements in menstrual cyclicity, lipid profile, and insulin resistance were associated with greater decreases in insulin resistance and fasting insulin.
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
TLDR
There is no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clmiphene; therefore, the use of meetformin in improving reproductive outcomes in women with PCOS appears to be limited.
...
1
2
3
4
5
...